Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 3
Submit an article Journal homepage
165
Views
3
CrossRef citations to date
0
Altmetric
Correspondence

CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target

Tilmann SchoberDr. von Hauner Children's Hospital, Department of Pediatrics, Ludwig-Maximilians-University, Munich, Germany;Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany;Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany
,
Theodor FramkeDepartment of Biostatistics, Hannover Medical School, Hannover, Germany
,
Anika GroßhennigDepartment of Biostatistics, Hannover Medical School, Hannover, Germany
,
Christoph KleinDr. von Hauner Children's Hospital, Department of Pediatrics, Ludwig-Maximilians-University, Munich, Germany
,
Hans KreipeInstitute of Pathology, Hannover Medical School, Hannover, Germany
&
Britta Maecker-KolhoffDepartment of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany;Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, GermanyCorrespondence[email protected]
Pages 832-833 | Received 05 Jun 2014, Accepted 19 Jun 2014, Published online: 03 Nov 2014

References

  • Hill BT, Tubbs Do RR, Smith MR. Complete remission of CD30 positive diffuse large B-cell lymphoma (DLBCL) in a patient with post-transplant lymphoproliferative disorder (PTLD) and end-stage renal disease treated with single agent brentuximab vedotin. Leuk Lymphoma 2014 Apr 9. [Epub ahead of print]
  • Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am J Transplant 2012;12:3069–3075.
  • Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196–206.
  • Deutsch YE, Tadmor T, Podack ER, et al. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011;52:1641–1654.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183–2189.
  • Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.
  • Ranjana A, Oki Y, Shstov AR, et al. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study. J Clin Oncol 2012;30(Suppl.): Abstract 8070.
  • Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095–3100.
  • Gregory CD, Edwards CF, Milner A, et al. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int J Cancer 1988;42:213–220.
  • Haque T, Chaggar T, Schafers J, et al. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011;83:311–316.
  • Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007;25:4902–4908.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.